APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chronic Metabolic Disease Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Chronic Metabolic Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025191 pages

Choose your research edition.

Industry ResearchChronic Metabolic Disease Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Metabolic Disease Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Chronic Metabolic Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Metabolic Disease Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Metabolic Disease Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Chronic Metabolic Disease Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Chronic Metabolic Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chronic Metabolic Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chronic Metabolic Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Chronic Metabolic Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Chronic Metabolic Disease Drug include Novartis, Novo Nordisk, Merck & Co. Inc, Eli Lilly, Pfizer, GlaxoSmithKline plc, Fresenius Kabi, Daiichi Sankyo and AstraZeneca plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chronic Metabolic Disease Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chronic Metabolic Disease Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chronic Metabolic Disease Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chronic Metabolic Disease Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Chronic Metabolic Disease Drug Segment by Company

Novartis

Novo Nordisk

Merck & Co. Inc

Eli Lilly

Pfizer

GlaxoSmithKline plc

Fresenius Kabi

Daiichi Sankyo

AstraZeneca plc

Torrent Labs

Regeneron Pharmaceuticals

Boehringer Ingelheim

Actelion Pharmaceuticals

Chronic Metabolic Disease Drug Segment by Type

Hyperlipidemia Drug

Hypertension Drug

High Blood Sugar Drug

High Uric Acid Drug

Chronic Metabolic Disease Drug Segment by Application

Hospital

Clinic

Others

Chronic Metabolic Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Metabolic Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Metabolic Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Metabolic Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chronic Metabolic Disease Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chronic Metabolic Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Chronic Metabolic Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Chronic Metabolic Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Chronic Metabolic Disease Drug Industry Trends Table 2. Chronic Metabolic Disease Drug Industry Drivers Table 3. Chronic Metabolic Disease Drug Industry Opportunities and Challenges Table 4. Chronic Metabolic Disease Drug Industry Restraints Table 5. Global Chronic Metabolic Disease Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Chronic Metabolic Disease Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Chronic Metabolic Disease Drug Sales by Manufacturers (tons) & (2021-2026) Table 8. Global Chronic Metabolic Disease Drug Sales Market Share by Manufacturers Table 9. Global Chronic Metabolic Disease Drug Average Sales Price (US$/ton) of Manufacturers (2021-2026) Table 10. Global Chronic Metabolic Disease Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Chronic Metabolic Disease Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Chronic Metabolic Disease Drug Manufacturers, Product Type & Application Table 13. Global Chronic Metabolic Disease Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Chronic Metabolic Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Hyperlipidemia Drug Table 17. Major Manufacturers of Hypertension Drug Table 18. Major Manufacturers of High Blood Sugar Drug Table 19. Major Manufacturers of High Uric Acid Drug Table 20. Global Chronic Metabolic Disease Drug Sales by Type 2021 VS 2025 VS 2032 (tons) Table 21. Global Chronic Metabolic Disease Drug Sales by Type (2021-2026) & (tons) Table 22. Global Chronic Metabolic Disease Drug Sales by Type (2027-2032) & (tons) Table 23. Global Chronic Metabolic Disease Drug Sales Market Share by Type (2021-2026) Table 24. Global Chronic Metabolic Disease Drug Sales Market Share by Type (2027-2032) Table 25. Global Chronic Metabolic Disease Drug Revenue by Type 2021 VS 2025 VS 2032 (tons) Table 26. Global Chronic Metabolic Disease Drug Revenue by Type (2021-2026) & (tons) Table 27. Global Chronic Metabolic Disease Drug Revenue by Type (2027-2032) & (tons) Table 28. Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2021-2026) Table 29. Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Others Table 33. Global Chronic Metabolic Disease Drug Sales by Application 2021 VS 2025 VS 2032 (tons) Table 34. Global Chronic Metabolic Disease Drug Sales by Application (2021-2026) & (tons) Table 35. Global Chronic Metabolic Disease Drug Sales by Application (2027-2032) & (tons) Table 36. Global Chronic Metabolic Disease Drug Sales Market Share by Application (2021-2026) Table 37. Global Chronic Metabolic Disease Drug Sales Market Share by Application (2027-2032) Table 38. Global Chronic Metabolic Disease Drug Revenue by Application 2021 VS 2025 VS 2032 (tons) Table 39. Global Chronic Metabolic Disease Drug Revenue by Application (2021-2026) & (tons) Table 40. Global Chronic Metabolic Disease Drug Revenue by Application (2027-2032) & (tons) Table 41. Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2021-2026) Table 42. Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2027-2032) Table 43. Global Chronic Metabolic Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (tons) Table 44. Global Chronic Metabolic Disease Drug Sales by Region (2021-2026) & (tons) Table 45. Global Chronic Metabolic Disease Drug Sales Market Share by Region (2021-2026) Table 46. Global Chronic Metabolic Disease Drug Sales Forecasted by Region (2027-2032) & (tons) Table 47. Global Chronic Metabolic Disease Drug Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Chronic Metabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 49. North America Chronic Metabolic Disease Drug Sales by Country (2021-2026) & (tons) Table 50. North America Chronic Metabolic Disease Drug Sales by Country (2027-2032) & (tons) Table 51. Europe Chronic Metabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 52. Europe Chronic Metabolic Disease Drug Sales by Country (2021-2026) & (tons) Table 53. Europe Chronic Metabolic Disease Drug Sales by Country (2027-2032) & (tons) Table 54. Asia Pacific Chronic Metabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 55. Asia Pacific Chronic Metabolic Disease Drug Sales by Country (2021-2026) & (tons) Table 56. Asia Pacific Chronic Metabolic Disease Drug Sales by Country (2027-2032) & (tons) Table 57. South America, Middle East and Africa Chronic Metabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 58. South America, Middle East and Africa Chronic Metabolic Disease Drug Sales by Country (2021-2026) & (tons) Table 59. South America, Middle East and Africa Chronic Metabolic Disease Drug Sales by Country (2027-2032) & (tons) Table 60. Global Chronic Metabolic Disease Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Chronic Metabolic Disease Drug Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Chronic Metabolic Disease Drug Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Chronic Metabolic Disease Drug Revenue Market Share by Region (2021-2026) Table 64. Global Chronic Metabolic Disease Drug Revenue Market Share by Region (2027-2032) Table 65. Novartis Company Information Table 66. Novartis Business Overview Table 67. Novartis Chronic Metabolic Disease Drug Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Novartis Chronic Metabolic Disease Drug Product Portfolio Table 69. Novartis Recent Development Table 70. Novo Nordisk Company Information Table 71. Novo Nordisk Business Overview Table 72. Novo Nordisk Chronic Metabolic Disease Drug Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Novo Nordisk Chronic Metabolic Disease Drug Product Portfolio Table 74. Novo Nordisk Recent Development Table 75. Merck & Co. Inc Company Information Table 76. Merck & Co. Inc Business Overview Table 77. Merck & Co. Inc Chronic Metabolic Disease Drug Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Merck & Co. Inc Chronic Metabolic Disease Drug Product Portfolio Table 79. Merck & Co. Inc Recent Development Table 80. Eli Lilly Company Information Table 81. Eli Lilly Business Overview Table 82. Eli Lilly Chronic Metabolic Disease Drug Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Eli Lilly Chronic Metabolic Disease Drug Product Portfolio Table 84. Eli Lilly Recent Development Table 85. Pfizer Company Information Table 86. Pfizer Business Overview Table 87. Pfizer Chronic Metabolic Disease Drug Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Pfizer Chronic Metabolic Disease Drug Product Portfolio Table 89. Pfizer Recent Development Table 90. GlaxoSmithKline plc Company Information Table 91. GlaxoSmithKline plc Business Overview Table 92. GlaxoSmithKline plc Chronic Metabolic Disease Drug Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. GlaxoSmithKline plc Chronic Metabolic Disease Drug Product Portfolio Table 94. GlaxoSmithKline plc Recent Development Table 95. Fresenius Kabi Company Information Table 96. Fresenius Kabi Business Overview Table 97. Fresenius Kabi Chronic Metabolic Disease Drug Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Fresenius Kabi Chronic Metabolic Disease Drug Product Portfolio Table 99. Fresenius Kabi Recent Development Table 100. Daiichi Sankyo Company Information Table 101. Daiichi Sankyo Business Overview Table 102. Daiichi Sankyo Chronic Metabolic Disease Drug Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Daiichi Sankyo Chronic Metabolic Disease Drug Product Portfolio Table 104. Daiichi Sankyo Recent Development Table 105. AstraZeneca plc Company Information Table 106. AstraZeneca plc Business Overview Table 107. AstraZeneca plc Chronic Metabolic Disease Drug Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. AstraZeneca plc Chronic Metabolic Disease Drug Product Portfolio Table 109. AstraZeneca plc Recent Development Table 110. Torrent Labs Company Information Table 111. Torrent Labs Business Overview Table 112. Torrent Labs Chronic Metabolic Disease Drug Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Torrent Labs Chronic Metabolic Disease Drug Product Portfolio Table 114. Torrent Labs Recent Development Table 115. Regeneron Pharmaceuticals Company Information Table 116. Regeneron Pharmaceuticals Business Overview Table 117. Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio Table 119. Regeneron Pharmaceuticals Recent Development Table 120. Boehringer Ingelheim Company Information Table 121. Boehringer Ingelheim Business Overview Table 122. Boehringer Ingelheim Chronic Metabolic Disease Drug Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Boehringer Ingelheim Chronic Metabolic Disease Drug Product Portfolio Table 124. Boehringer Ingelheim Recent Development Table 125. Actelion Pharmaceuticals Company Information Table 126. Actelion Pharmaceuticals Business Overview Table 127. Actelion Pharmaceuticals Chronic Metabolic Disease Drug Sales (tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Actelion Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio Table 129. Actelion Pharmaceuticals Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Chronic Metabolic Disease Drug Distributors List Table 133. Chronic Metabolic Disease Drug Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Chronic Metabolic Disease Drug Product Image Figure 2. Global Chronic Metabolic Disease Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Metabolic Disease Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Chronic Metabolic Disease Drug Sales (2021-2032) & (tons) Figure 5. Global Chronic Metabolic Disease Drug Average Price (US$/ton) & (2021-2032) Figure 6. Global Top 5 and 10 Chronic Metabolic Disease Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Hyperlipidemia Drug Image Figure 9. Hypertension Drug Image Figure 10. High Blood Sugar Drug Image Figure 11. High Uric Acid Drug Image Figure 12. Global Chronic Metabolic Disease Drug Sales by Type (2021 VS 2025 VS 2032) & (tons) Figure 13. Global Chronic Metabolic Disease Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Chronic Metabolic Disease Drug Sales Market Share by Type (2021-2032) Figure 15. Global Chronic Metabolic Disease Drug Revenue by Type (2021 VS 2025 VS 2032) & (tons) Figure 16. Global Chronic Metabolic Disease Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Chronic Metabolic Disease Drug Sales by Application (2021 VS 2025 VS 2032) & (tons) Figure 22. Global Chronic Metabolic Disease Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Chronic Metabolic Disease Drug Sales Market Share by Application (2021-2032) Figure 24. Global Chronic Metabolic Disease Drug Revenue by Application (2021 VS 2025 VS 2032) & (tons) Figure 25. Global Chronic Metabolic Disease Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2021-2032) Figure 27. North America Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 28. North America Chronic Metabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 29. U.S. Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 30. Canada Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 31. Mexico Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 32. Europe Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 33. Europe Chronic Metabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 34. Germany Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 35. France Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 36. U.K. Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 37. Italy Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 38. Netherlands Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 39. Asia Pacific Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 40. Asia Pacific Chronic Metabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 41. China Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 42. Japan Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 43. South Korea Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 44. Southeast Asia Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 45. India Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 46. Australia Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 47. South America, Middle East and Africa Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 48. South America, Middle East and Africa Chronic Metabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 49. Brazil Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 50. South Africa Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 51. Saudi Arabia Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 52. Turkey Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 53. Argentina Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 54. UAE Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 55. Egypt Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 56. Chile Chronic Metabolic Disease Drug Sales and Growth Rate (2021-2032) & (tons) Figure 57. Global Chronic Metabolic Disease Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Chronic Metabolic Disease Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Figure 60. North America Chronic Metabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Figure 62. Europe Chronic Metabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Chronic Metabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Chronic Metabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Chronic Metabolic Disease Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Chronic Metabolic Disease Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Hyperlipidemia Drug
  • Hypertension Drug
  • High Blood Sugar Drug
  • High Uric Acid Drug
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis
  • Novo Nordisk
  • Merck & Co. Inc
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline plc
  • Fresenius Kabi
  • Daiichi Sankyo
  • AstraZeneca plc
  • Torrent Labs
  • Regeneron Pharmaceuticals
  • Boehringer Ingelheim
  • Actelion Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Chronic Metabolic Disease Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Chronic Metabolic Disease Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Chronic Metabolic Disease Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Chronic Metabolic Disease Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Chronic Metabolic Disease Drug Market Dynamics
  1. 2.1 Chronic Metabolic Disease Drug Industry Trends
  2. 2.2 Chronic Metabolic Disease Drug Industry Drivers
  3. 2.3 Chronic Metabolic Disease Drug Industry Opportunities and Challenges
  4. 2.4 Chronic Metabolic Disease Drug Industry Restraints
3 Chronic Metabolic Disease Drug Market by Manufacturers
  1. 3.1 Global Chronic Metabolic Disease Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Chronic Metabolic Disease Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Chronic Metabolic Disease Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Chronic Metabolic Disease Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chronic Metabolic Disease Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Chronic Metabolic Disease Drug Manufacturers, Product Type & Application
  7. 3.7 Global Chronic Metabolic Disease Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chronic Metabolic Disease Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chronic Metabolic Disease Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chronic Metabolic Disease Drug Tier 1, Tier 2, and Tier 3
4 Chronic Metabolic Disease Drug Market by Type
  1. 4.1 Chronic Metabolic Disease Drug Type Introduction
  2. 4.1.1 Hyperlipidemia Drug
  3. 4.1.2 Hypertension Drug
  4. 4.1.3 High Blood Sugar Drug
  5. 4.1.4 High Uric Acid Drug
  6. 4.2 Global Chronic Metabolic Disease Drug Sales by Type
  7. 4.2.1 Global Chronic Metabolic Disease Drug Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Chronic Metabolic Disease Drug Sales by Type (2021-2032)
  9. 4.2.3 Global Chronic Metabolic Disease Drug Sales Market Share by Type (2021-2032)
  10. 4.3 Global Chronic Metabolic Disease Drug Revenue by Type
  11. 4.3.1 Global Chronic Metabolic Disease Drug Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Chronic Metabolic Disease Drug Revenue by Type (2021-2032)
  13. 4.3.3 Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2021-2032)
5 Chronic Metabolic Disease Drug Market by Application
  1. 5.1 Chronic Metabolic Disease Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Chronic Metabolic Disease Drug Sales by Application
  6. 5.2.1 Global Chronic Metabolic Disease Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chronic Metabolic Disease Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Chronic Metabolic Disease Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Chronic Metabolic Disease Drug Revenue by Application
  10. 5.3.1 Global Chronic Metabolic Disease Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Chronic Metabolic Disease Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2021-2032)
6 Global Chronic Metabolic Disease Drug Sales by Region
  1. 6.1 Global Chronic Metabolic Disease Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chronic Metabolic Disease Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Chronic Metabolic Disease Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Chronic Metabolic Disease Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Chronic Metabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Chronic Metabolic Disease Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Chronic Metabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Chronic Metabolic Disease Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Chronic Metabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Chronic Metabolic Disease Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Chronic Metabolic Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Chronic Metabolic Disease Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Chronic Metabolic Disease Drug Revenue by Region
  1. 7.1 Global Chronic Metabolic Disease Drug Revenue by Region
  2. 7.1.1 Global Chronic Metabolic Disease Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Chronic Metabolic Disease Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Chronic Metabolic Disease Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Chronic Metabolic Disease Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Chronic Metabolic Disease Drug Revenue (2021-2032)
  8. 7.2.2 North America Chronic Metabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Chronic Metabolic Disease Drug Revenue (2021-2032)
  11. 7.3.2 Europe Chronic Metabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Chronic Metabolic Disease Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Chronic Metabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Chronic Metabolic Disease Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Chronic Metabolic Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Chronic Metabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Chronic Metabolic Disease Drug Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Chronic Metabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Chronic Metabolic Disease Drug Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 Merck & Co. Inc
  14. 8.3.1 Merck & Co. Inc Company Information
  15. 8.3.2 Merck & Co. Inc Business Overview
  16. 8.3.3 Merck & Co. Inc Chronic Metabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co. Inc Chronic Metabolic Disease Drug Product Portfolio
  18. 8.3.5 Merck & Co. Inc Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Chronic Metabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Chronic Metabolic Disease Drug Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Chronic Metabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Chronic Metabolic Disease Drug Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GlaxoSmithKline plc
  32. 8.6.1 GlaxoSmithKline plc Company Information
  33. 8.6.2 GlaxoSmithKline plc Business Overview
  34. 8.6.3 GlaxoSmithKline plc Chronic Metabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline plc Chronic Metabolic Disease Drug Product Portfolio
  36. 8.6.5 GlaxoSmithKline plc Recent Developments
  37. 8.7 Fresenius Kabi
  38. 8.7.1 Fresenius Kabi Company Information
  39. 8.7.2 Fresenius Kabi Business Overview
  40. 8.7.3 Fresenius Kabi Chronic Metabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Fresenius Kabi Chronic Metabolic Disease Drug Product Portfolio
  42. 8.7.5 Fresenius Kabi Recent Developments
  43. 8.8 Daiichi Sankyo
  44. 8.8.1 Daiichi Sankyo Company Information
  45. 8.8.2 Daiichi Sankyo Business Overview
  46. 8.8.3 Daiichi Sankyo Chronic Metabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo Chronic Metabolic Disease Drug Product Portfolio
  48. 8.8.5 Daiichi Sankyo Recent Developments
  49. 8.9 AstraZeneca plc
  50. 8.9.1 AstraZeneca plc Company Information
  51. 8.9.2 AstraZeneca plc Business Overview
  52. 8.9.3 AstraZeneca plc Chronic Metabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca plc Chronic Metabolic Disease Drug Product Portfolio
  54. 8.9.5 AstraZeneca plc Recent Developments
  55. 8.10 Torrent Labs
  56. 8.10.1 Torrent Labs Company Information
  57. 8.10.2 Torrent Labs Business Overview
  58. 8.10.3 Torrent Labs Chronic Metabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Torrent Labs Chronic Metabolic Disease Drug Product Portfolio
  60. 8.10.5 Torrent Labs Recent Developments
  61. 8.11 Regeneron Pharmaceuticals
  62. 8.11.1 Regeneron Pharmaceuticals Company Information
  63. 8.11.2 Regeneron Pharmaceuticals Business Overview
  64. 8.11.3 Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio
  66. 8.11.5 Regeneron Pharmaceuticals Recent Developments
  67. 8.12 Boehringer Ingelheim
  68. 8.12.1 Boehringer Ingelheim Company Information
  69. 8.12.2 Boehringer Ingelheim Business Overview
  70. 8.12.3 Boehringer Ingelheim Chronic Metabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Boehringer Ingelheim Chronic Metabolic Disease Drug Product Portfolio
  72. 8.12.5 Boehringer Ingelheim Recent Developments
  73. 8.13 Actelion Pharmaceuticals
  74. 8.13.1 Actelion Pharmaceuticals Company Information
  75. 8.13.2 Actelion Pharmaceuticals Business Overview
  76. 8.13.3 Actelion Pharmaceuticals Chronic Metabolic Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Actelion Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio
  78. 8.13.5 Actelion Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chronic Metabolic Disease Drug Value Chain Analysis
  2. 9.1.1 Chronic Metabolic Disease Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chronic Metabolic Disease Drug Production Mode & Process
  6. 9.2 Chronic Metabolic Disease Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chronic Metabolic Disease Drug Distributors
  9. 9.2.3 Chronic Metabolic Disease Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst